Need Any Help ?

Home
Enquire
Register
About
SHOWCASE
Partners
KEYNOTE
AGENDA
1-2-1 partnering
INVESTORS
CONTACT US

'); /* Uncomment for mobile button that says 'MENU' $('.custom-menu-primary .hs-menu-wrapper').before('

MENU

'); */ $('.custom-menu-primary .flyouts .hs-item-has-children > a').after('

'); $('.mobile-trigger').click(function() { $(this).next('.custom-menu-primary .hs-menu-wrapper').slideToggle(250); $('body').toggleClass('mobile-open'); $('.child-trigger').removeClass('child-open'); $('.hs-menu-children-wrapper').slideUp(250); return false; }); $('.child-trigger').click(function() { $(this).parent().siblings('.hs-item-has-children').find('.child-trigger').removeClass('child-open'); $(this).parent().siblings('.hs-item-has-children').find('.hs-menu-children-wrapper').slideUp(250); $(this).next('.hs-menu-children-wrapper').slideToggle(250); $(this).next('.hs-menu-children-wrapper').children('.hs-item-has-children').find('.hs-menu-children-wrapper').slideUp(250); $(this).next('.hs-menu-children-wrapper').children('.hs-item-has-children').find('.child-trigger').removeClass('child-open'); $(this).toggleClass('child-open'); return false; }); });

AMAL THERAPEUTICS

AMAL Therapeutics SA is a spin-off from the University of Geneva active in cancer immunotherapy. AMAL has developed a unique protein-based immunization platform providing activation signal to dendritic cells simultaneously to priming both helper and killer cells for various antigens and HLA restrictions. This first-in-class platform is offering the opportunity to develop standardized and indication-tailored active immunotherapies.

www.amaltherapeutics.com